fda warning letter glp-1 solution september 9 2025 Drug Recalls and Warnings: Illegal Sales and Misleading Marketing by Novo Nordisk and Eli Lilly Prescription Drug Freight Fraud Report,

Specifically formulated for GLP-1 users

Patients with unfavorable genetic profiles often benefit from longer treatment duration, while those with favorable markers may achieve durable results on shorter courses

Head-to-head data show HbA1c reductions of 2.02.3 percentage points versus 1.61.9 points for single-receptor comparators [2]Eli Lilly, SURPASS Program Results, lilly.com

This is true regardless of whether weight loss happens through diet, surgery, or medication

Novo is also hoping to expand treatment options for people living with obesity and type 2 diabetes with its investigational drug, CagriSema

Think you know the GLP-1 landscape